Sugi Predict

Sugi Predict / Compounds / SCHEMBL7186942

SCHEMBL7186942

SCHEMBL7186942

COc1ccc(PC(=O)c2c(C)cc(C)c(C)c2C)c(OC)c1.[LiH]

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.39
▸ MAPT P10636 5/20 0.38
▸ GAA P10253 3/20 0.38
▸ LMNA P02545 3/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ CA12 O43570 1/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CA7 P43166 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ CA14 Q9ULX7 1/20 0.37
▸ SMN1; SMN2 Q16637 4/20 0.36
▸ CYP3A4 P08684 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7186950 0.97 KMT2A (0.39) KMT2AMAPTGAALMNARAB9A
SCHEMBL7178301 0.89 CYP3A4 (0.37) KMT2AGAALMNARAB9ANPSR1
SCHEMBL7182499 0.86 KMT2A (0.41) KMT2AMAPTGAALMNARAB9A
SCHEMBL7188541 0.84 KMT2A (0.45) KMT2AMAPTGAALMNARAB9A
Lithium SCHEMBL7182503 0.84 KMT2A (0.41) KMT2AMAPTGAALMNARAB9A
SCHEMBL7186821 0.83 LMNA (0.37) LMNAKDM4ENPC1ALDH1A1CA1
SCHEMBL7188265 0.83 KMT2A (0.51) KMT2AMAPTGAALMNANPSR1
SCHEMBL7180594 0.83 KMT2A (0.39) KMT2AMAPTGAALMNANPSR1
SCHEMBL7185361 0.83 KMT2A (0.32) KMT2ALMNACYP3A4
SCHEMBL7188912 0.82 CYP3A4 (0.39) KMT2AMAPTGAANPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885MAPT 4870/4885GAA 4753/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885MAPT 4859/4885GAA 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.